Human Genome Sciences Inc, under license from Cambridge Antibody Technology Ltd, is developing lexatumumab, an intravenous human agonistic mAb to TNF-related apoptosis-inducing ligand (TRAIL) receptor 2, for the potential treatment of cancer. Phase II clinical trials of lexatumumab are underway.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
lexatumumab intravenous
8
intravenous human
8
human agonistic
8
agonistic mab
8
trail receptor
8
drug evaluation
4
evaluation lexatumumab
4
mab targeting
4
targeting trail
4
receptor human
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!